Implementing tuberculosis preventive treatment in high-prevalence settings.

Mycobacterium tuberculosis latent tuberculosis patient-centered care preventive therapy prophylaxis

Journal

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
ISSN: 1878-3511
Titre abrégé: Int J Infect Dis
Pays: Canada
ID NLM: 9610933

Informations de publication

Date de publication:
Dec 2021
Historique:
received: 03 02 2021
revised: 21 02 2021
accepted: 23 02 2021
pubmed: 16 3 2021
medline: 22 12 2021
entrez: 15 3 2021
Statut: ppublish

Résumé

Latent tuberculosis infection affects one quarter of the world's population, and effective therapies are available. However, scale-up of tuberculosis preventive treatment (TPT) remains limited. We describe strategies to support scale-up of TPT in high-prevalence settings, where the potential benefit for affected individuals is considerable. Patients must be at the centre of policies to scale-up TPT. Addressing the health system requirements for scale-up will ensure that programs can deliver treatment safely, efficiently and sustainably. Further research is required to adapt TPT to local contexts, and develop new shorter treatments that will be suitable for wide-scale deployment.

Identifiants

pubmed: 33716196
pii: S1201-9712(21)00180-6
doi: 10.1016/j.ijid.2021.02.094
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

S13-S15

Informations de copyright

Crown Copyright © 2021. Published by Elsevier Ltd. All rights reserved.

Auteurs

Greg J Fox (GJ)

Faculty of Medicine and Health, The University of Sydney, NSW, 2006, Australia; The Woolcock Institute of Medical Research, Glebe, NSW, 2006, Australia. Electronic address: greg.fox@sydney.edu.au.

Thu Anh Nguyen (TA)

The Woolcock Institute of Medical Research, Hanoi, 10000, Viet Nam.

Mikaela Coleman (M)

Faculty of Medicine and Health, The University of Sydney, NSW, 2006, Australia; Centenary Institute, Camperdown, NSW, 2050, Australia.

Anete Trajman (A)

Social Medicine Institute, State University of Rio de Janeiro, Brazil; McGill University, Montreal, Canada.

Kavindhran Velen (K)

Faculty of Medicine and Health, The University of Sydney, NSW, 2006, Australia; The Woolcock Institute of Medical Research, Glebe, NSW, 2006, Australia.

Ben J Marais (BJ)

Faculty of Medicine and Health, The University of Sydney, NSW, 2006, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH